Difference between revisions of "Apatinib (Aitan)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Category:Chemotherapy" to "Category:Chemotherapeutic")
m
Line 10: Line 10:
 
*'''Generic name:''' rivoceranib
 
*'''Generic name:''' rivoceranib
 
*'''Brand name:''' Aitan
 
*'''Brand name:''' Aitan
−
 
−
==References==
 
−
# Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016 May 1;34(13):1448-54. Epub 2016 Feb 16. [http://jco.ascopubs.org/content/34/13/1448.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26884585 PubMed]
 
  
 
[[Category:Drugs]]
 
[[Category:Drugs]]

Revision as of 16:39, 24 April 2019

Mechanism of action

From the NCI Drug Dictionary: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.

Diseases for which it is used

Also known as

  • Code name: YN968D1
  • Generic name: rivoceranib
  • Brand name: Aitan
Retrieved from "https://hemonc.org/w/index.php?title=Apatinib_(Aitan)&oldid=36549"